The University of Kansas Cancer Center The University of South Alabama, Mitchell Cancer Institute The University of Texas MD Anderson Cancer Center The Winthrop P. Rockefeller Cancer Institute at the ...

The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant ...

NP Theresa Stukus and NP Nelli Zafman discuss how differences among available frontline antibody-drug conjugates (ADCs) can ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

FDA approves cabozantinib capsules for RCC, HCC, and epNET. Review key dosing conversions and safety guidelines for oncology ...

NP Theresa Stukus and NP Nelli Zafman discuss the unique challenges of caring for younger patients with metastatic ...

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in ...

FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for adult patients with ESR1-mutated HR+/HER2- ...

Stephanie Sorrentino, BSN, OCN, discusses operational strategies, toxicity management, and patient education in frontline multiple myeloma care.

FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly ...

Beth Sandy, CRNP, of Penn Medicine discusses therapeutic advances in thoracic oncology, toxicity management, and overcoming ...

Surbhi Sidana, MD, discusses how the FDA-approved oral CELMoD iberdomide expands access and impacts nursing care in multiple ...